Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
HDAC11 inhibition triggers bimodal thermogenic pathways to circumvent adipocyte catecholamine resistance
Emma L. Robinson, … , Jennifer L. Matsuda, Timothy A. McKinsey
Emma L. Robinson, … , Jennifer L. Matsuda, Timothy A. McKinsey
Published August 22, 2023
Citation Information: J Clin Invest. 2023;133(19):e168192. https://doi.org/10.1172/JCI168192.
View: Text | PDF
Research Article Metabolism

HDAC11 inhibition triggers bimodal thermogenic pathways to circumvent adipocyte catecholamine resistance

  • Text
  • PDF
Abstract

Stimulation of adipocyte β-adrenergic receptors (β-ARs) induces expression of uncoupling protein 1 (UCP1), promoting nonshivering thermogenesis. Association of β-ARs with a lysine-myristoylated form of A kinase–anchoring protein 12 (AKAP12, also known as gravin-α) is required for downstream signaling that culminates in UCP1 induction. Conversely, demyristoylation of gravin-α by histone deacetylase 11 (HDAC11) suppresses this pathway. Whether inhibition of HDAC11 in adipocytes is sufficient to drive UCP1 expression independently of β-ARs is not known. Here, we demonstrate that adipocyte-specific deletion of HDAC11 in mice leads to robust induction of UCP1 in adipose tissue (AT), resulting in increased body temperature. These effects are mimicked by treating mice in vivo or human AT ex vivo with an HDAC11-selective inhibitor, FT895. FT895 triggers biphasic, gravin-α myristoylation–dependent induction of UCP1 protein expression, with a noncanonical acute response that is posttranscriptional and independent of protein kinase A (PKA), and a delayed response requiring PKA activity and new Ucp1 mRNA synthesis. Remarkably, HDAC11 inhibition promotes UCP1 expression even in models of adipocyte catecholamine resistance where β-AR signaling is blocked. These findings define cell-autonomous, multimodal roles for HDAC11 as a suppressor of thermogenesis, and highlight the potential of inhibiting HDAC11 to therapeutically alter AT phenotype independently of β-AR stimulation.

Authors

Emma L. Robinson, Rushita A. Bagchi, Jennifer L. Major, Bryan C. Bergman, Jennifer L. Matsuda, Timothy A. McKinsey

×

Figure 8

HDAC11 inhibition promotes UCP1 expression and PKA signaling in cell-based models of catecholamine resistance.

Options: View larger image (or click on image) Download as PowerPoint
HDAC11 inhibition promotes UCP1 expression and PKA signaling in cell-bas...
(A) Schematic representation of the cell culture experiment to determine whether HDAC11 inhibition promotes adipocyte UCP1 expression and PKA signaling in the context of downregulated β3-adrenergic receptor (β3-AR) expression due to chronic agonist exposure. (B) Immunoblot analysis of 3T3-L1 cells pretreated with vehicle or the β3-AR agonist CL-316,243 (CL) for 20 hours followed by 1-hour treatment with vehicle (–), CL, the adenylyl cyclase activator forskolin (FSK), or FT895; n = 2 technical replicates/condition. (C) Densitometric analysis of UCP1 expression in B, and from 2 additional independent experiments (blots not shown), normalized to GAPDH and plotted as fold-change relative to CL treatment alone. Expression of UCP1 with vehicle pretreatment + CL is set to 1 within each independent experiment. Data are presented as mean + SEM, with *P < 0.05 as determined by 1-way ANOVA with Tukey’s multiple-comparison test. (D) These same samples were independently immunoblotted with an antibody that recognizes proteins containing phospho-serine/threonine residues within a consensus PKA target site (RRXS*/T*). (E) Schematic representation of the cell culture experiment to determine whether HDAC11 inhibition promotes adipocyte UCP1 expression and PKA signaling in the context of catecholamine resistance due to knockdown of β3-AR expression. (F) Immunoblot analysis of the indicated proteins in homogenates of 3T3-L1 cells; n = 3 technical replicates/condition. (G) Densitometric analysis of UCP1 expression in F normalized to GAPDH and plotted as fold-change relative to Lenti-shAdrb3 + CL. Data are presented as mean + SEM, with *P < 0.05 determined by 1-way ANOVA with Tukey’s multiple-comparison test. (H) Immunoblot analysis with the anti–phospho-PKA-substrate antibody.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts